A publication entitled, “Guidelines for the management of neovascular age-related macular degeneration by the European Society of Retina Specialists (EURETINA)”, published in the British Journal… Read More »EURETINA guidelines publication ranked in first place of
Research, based at the Department of Ophthalmology at the University of Kiel, Germany, has indicated that aflibercept and bevacizumab may interfere with the physiology of… Read More »Results of small cell study suggests aflibercept and bevacizumab may impair wound healing capability of porcine RPE cells
Amarantus Biosciences Holdings Inc., with bases in San Francisco, USA and Geneva, Switzerland have announced the exercise of an option to exclusively license worldwide rights… Read More »Amarantus Bioscience Holdings Inc., licenses technology from the Bascom Palmer Eye Institute
Interim data from a phase II clinical study (ClinicalTrials.gov ID: NCT01678963) evaluating an ocular formulation of “squalamine” – an aminosterol compound originally identified in sharks… Read More »Interim Phase II trial data of a shark-derived squalamine compound indicates benefit in wet AMD patients
Researchers based at Columbia University, New York, USA, have published novel research illustrating both a putative gene therapy treatment for recessive retinitis pigmentosa (RP), and… Read More »Induced-pluripotent stem (iPS)-derived RPE cells from patients augment gene therapy for recessive RP
In the latest round of claim and counter-claim following a hostile takeover bid from Valeant Pharmaceuticals (NYSE: VRX) for Allergan Inc., (NYSE: AGN), Valeant and… Read More »Allergan and Valeant continue to trade blows in hostile takeover bid
A phase 1 clinical study of novel plasma kallikrein inhibitors for the treatment of DME (diabetic macular edema) has been announced by KalVista Pharmaceuticals, a… Read More »Phase I trial of novel plasma kallikrein inhibitors for treatment of DME is initiated by UK company
Researchers, based at the University of Pennsylvania, have shown that patients with a particular uveal melanoma mutational profile may carry a 10-fold increased risk of… Read More »Mutation profiling of uveal melanoma genes reveals significantly different patient prognosis
Pfenex Inc., San Diego, a clinical-stage biotechnology company developing biosimilar therapeutics has closed its previously announced initial public offering of 8,333,333 shares of its common… Read More »US-based biosimilar company targeting Lucentis market announces IPO price
A collaborative research group, led by the McGill University Health Centre, Montreal, Canada, with funding from QLT Inc., (NASDAQ: QLTI; TSX: QLT), have published the… Read More »Oral synthetic retinoid replacement compound improves vision in LCA patients